

Jos J Lucas

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7945826/jose-j-lucas-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

8,672
citations

48
h-index

92
g-index

117
ext. papers

9,559
ext. citations

8.5
avg, IF

5.7
L-index

#	Paper	IF	Citations
112	Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. <i>Cell</i> , 2000 , 101, 57-66	56.2	899
111	Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. <i>EMBO Journal</i> , 2001 , 20, 27-39	13	670
110	Role of tau protein in both physiological and pathological conditions. <i>Physiological Reviews</i> , 2004 , 84, 361-84	47.9	641
109	Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. <i>Journal of Biological Chemistry</i> , 2003 , 278, 45937-45	5.4	393
108	Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. <i>Journal of Neurochemistry</i> , 2002 , 83, 1529-33	6	291
107	Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. <i>Nature</i> , 1998 , 393, 175-8	50.4	276
106	Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. <i>European Journal of Neuroscience</i> , 2007 , 25, 81-6	3.5	268
105	Neuronal induction of the immunoproteasome in Huntington's disease. <i>Journal of Neuroscience</i> , 2003 , 23, 11653-61	6.6	218
104	Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. <i>Journal of Neuroscience</i> , 2006 , 26, 5083-90	6.6	217
103	GSK3: a possible link between beta amyloid peptide and tau protein. <i>Experimental Neurology</i> , 2010 , 223, 322-5	5.7	200
102	Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. <i>FASEB Journal</i> , 2009 , 23, 1893-906	0.9	180
101	FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. <i>Molecular and Cellular Neurosciences</i> , 2001 , 18, 702-14	4.8	176
100	Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. <i>Journal of Neurochemistry</i> , 2006 , 99, 1445-55	6	169
99	GSK3 and tau: two convergence points in Alzheimer's disease. <i>Journal of Alzheimers Disease</i> , 2013 , 33 Suppl 1, S141-4	4.3	162
98	Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. <i>Brain</i> , 2011 , 134, 119-36	11.2	154
97	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009 , 16, 297-309	6	143
96	Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. <i>Journal of Neuroscience</i> , 2001 , 21, 8772-81	6.6	136

95	Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. <i>Journal of Neuroscience</i> , 1998 , 18, 5537-44	6.6	136
94	Huntington's disease is a four-repeat tauopathy with tau nuclear rods. <i>Nature Medicine</i> , 2014 , 20, 881-5	50.5	135
93	Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. <i>European Journal of Neuroscience</i> , 2006 , 23, 649-58	3.5	107
92	Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. <i>Journal of Biological Chemistry</i> , 2004 , 279, 3801-6	5.4	103
91	New players in the 5-HT receptor field: genes and knockouts. <i>Trends in Pharmacological Sciences</i> , 1995 , 16, 246-52	13.2	102
90	N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. <i>Journal of Biological Chemistry</i> , 2007 , 282, 22406-13	5.4	99
89	Coexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. <i>Neurobiology of Aging</i> , 2006 , 27, 1258-68	5.6	96
88	Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome. <i>Brain Pathology</i> , 2016 , 26, 593-605	6	96
87	Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. <i>Brain Research</i> , 2002 , 929, 236-42	3.7	93
86	Molecular mechanisms of pain: serotonin1A receptor agonists trigger transactivation by c-fos of the prodynorphin gene in spinal cord neurons. <i>Neuron</i> , 1993 , 10, 599-611	13.9	90
85	Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. <i>Neurobiology of Disease</i> , 2010 , 37, 622-9	7.5	87
84	5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. <i>Molecular Pharmacology</i> , 1997 , 51, 755-63	4.3	81
83	Modulation of the effects of cocaine by 5-HT1B receptors: a comparison of knockouts and antagonists. <i>Pharmacology Biochemistry and Behavior</i> , 2000 , 67, 559-66	3.9	81
82	Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. <i>Journal of Neurochemistry</i> , 2006 , 98, 1585-96	6	77
81	Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. <i>Journal of Neuroscience</i> , 2010 , 30, 3675-88	6.6	76
80	CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures. <i>Brain</i> , 2013 , 136, 577-92	11.2	74
79	Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 13986-91	11.5	72
78	Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004 , 63, 484-98	3.1	69

77	Ubiquitin-proteasome system involvement in Huntington's disease. <i>Frontiers in Molecular Neuroscience</i> , 2014 , 7, 77	6.1	67
76	Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. <i>Free Radical Biology and Medicine</i> , 2010 , 49, 612-21	7.8	66
75	In vivo inhibition of the mitochondrial H ⁺ -ATP synthase in neurons promotes metabolic preconditioning. <i>EMBO Journal</i> , 2014 , 33, 762-78	13	64
74	NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2432-45	15.9	64
73	Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing. <i>Nature</i> , 2018 , 560, 441-446	50.4	62
72	GSK3 β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. <i>Hippocampus</i> , 2011 , 21, 910-22	3.5	61
71	Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. <i>Journal of Neuroscience</i> , 2005 , 25, 9773-81	6.6	61
70	The role of GSK3 in Alzheimer disease. <i>Brain Research Bulletin</i> , 2009 , 80, 248-50	3.9	59
69	Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. <i>Journal of Neuroscience</i> , 2011 , 31, 8150-62	6.6	55
68	Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. <i>EMBO Journal</i> , 2007 , 26, 2743-54	13	54
67	Is the ubiquitin-proteasome system impaired in Huntington's disease?. <i>Cellular and Molecular Life Sciences</i> , 2007 , 64, 2245-57	10.3	54
66	Co-induction of jun B and c-fos in a subset of neurons in the spinal cord. <i>Oncogene</i> , 1991 , 6, 223-7	9.2	54
65	GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. <i>Frontiers in Molecular Neuroscience</i> , 2011 , 4, 45	6.1	49
64	Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. <i>Journal of Neuroscience</i> , 2004 , 24, 9361-71	6.6	47
63	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system. <i>Acta Neuropathologica</i> , 2016 , 131, 411-25	14.3	44
62	PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. <i>Cell Death and Differentiation</i> , 2010 , 17, 324-35	12.7	42
61	The ubiquitin-proteasome system in Huntington's disease. <i>Neuroscientist</i> , 2005 , 11, 583-94	7.6	42
60	Tau in neurodegenerative diseases: tau phosphorylation and assembly. <i>Neurotoxicity Research</i> , 2004 , 6, 477-82	4.3	39

59	Lithium, a potential protective drug in Alzheimer's disease. <i>Neurodegenerative Diseases</i> , 2008 , 5, 247-9	2.3	37
58	Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. <i>Neurotoxicity Research</i> , 2004 , 6, 463-8	4.3	36
57	GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. <i>Neurobiology of Aging</i> , 2003 , 24, 1087-94	5.6	36
56	Impaired ATF6 β processing, decreased Rheb and neuronal cell cycle re-entry in Huntington's disease. <i>Neurobiology of Disease</i> , 2011 , 41, 23-32	7.5	35
55	Increased neurotransmitter release at the neuromuscular junction in a mouse model of polyglutamine disease. <i>Journal of Neuroscience</i> , 2011 , 31, 1106-13	6.6	34
54	Protective neuronal induction of ATF5 in endoplasmic reticulum stress induced by status epilepticus. <i>Brain</i> , 2013 , 136, 1161-76	11.2	33
53	Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. <i>Trends in Neurosciences</i> , 2004 , 27, 66-9	13.3	33
52	Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. <i>Neurobiology of Disease</i> , 2009 , 36, 461-9	7.5	32
51	BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. <i>Journal of Neuroscience Research</i> , 2007 , 85, 2756-69	4.4	29
50	Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. <i>Human Molecular Genetics</i> , 2015 , 24, 5040-52	5.6	27
49	Presynaptic dysfunction in Huntington's disease. <i>Biochemical Society Transactions</i> , 2010 , 38, 488-92	5.1	26
48	β Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. <i>Human Molecular Genetics</i> , 2012 , 21, 495-510	5.6	25
47	Mice with a naturally occurring DISC1 mutation display a broad spectrum of behaviors associated to psychiatric disorders. <i>Frontiers in Behavioral Neuroscience</i> , 2014 , 8, 253	3.5	22
46	Faulty splicing and cytoskeleton abnormalities in Huntington's disease. <i>Brain Pathology</i> , 2016 , 26, 772-778		21
45	Age-dependent decline of motor neocortex but not hippocampal performance in heterozygous BDNF mice correlates with a decrease of cortical PSD-95 but an increase of hippocampal TrkB levels. <i>Experimental Neurology</i> , 2012 , 237, 335-45	5.7	21
44	Effects of partial suppression of parkin on huntingtin mutant R6/1 mice. <i>Brain Research</i> , 2009 , 1281, 91-100	3.7	21
43	Tau phosphorylation in hippocampus results in toxic gain-of-function. <i>Biochemical Society Transactions</i> , 2010 , 38, 977-80	5.1	21
42	Assembly in vitro of tau protein and its implications in Alzheimer's disease. <i>Current Alzheimer Research</i> , 2004 , 1, 97-101	3	21

41	Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. <i>European Journal of Neuroscience</i> , 2002 , 16, 355-9	3.5	19
40	βSynuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology. <i>Autophagy</i> , 2012 , 8, 431-2	10.2	17
39	Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs. <i>Brain Research</i> , 2002 , 935, 65-72	3.7	17
38	Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus. <i>Cell Death and Disease</i> , 2018 , 9, 969	9.8	16
37	MAP2 Splicing is Altered in Huntington's Disease. <i>Brain Pathology</i> , 2017 , 27, 181-189	6	15
36	Looking for novel functions of tau. <i>Biochemical Society Transactions</i> , 2012 , 40, 653-5	5.1	15
35	Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome. <i>Neurobiology of Disease</i> , 2019 , 127, 210-222	7.5	14
34	Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2019 , 13, 574	6.1	14
33	Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice. <i>Human Molecular Genetics</i> , 2014 , 23, 767-81	5.6	14
32	Mutant huntingtin affects endocytosis in striatal cells by altering the binding of AP-2 to membranes. <i>Experimental Neurology</i> , 2013 , 241, 75-83	5.7	13
31	Peripheral noxious stimulation induces CREM expression in dorsal horn: involvement of glutamate. <i>European Journal of Neuroscience</i> , 1997 , 9, 2778-83	3.5	12
30	Nuclear localization of beta-catenin in adult mouse thalamus correlates with low levels of GSK-3beta. <i>NeuroReport</i> , 1999 , 10, 2699-703	1.7	12
29	Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury. <i>Molecular Neurodegeneration</i> , 2017 , 12, 21	19	11
28	Tau-positive nuclear indentations in P301S tauopathy mice. <i>Brain Pathology</i> , 2017 , 27, 314-322	6	9
27	Pathogenic SREK1 decrease in Huntington's disease lowers TAF1 mimicking X-linked dystonia parkinsonism. <i>Brain</i> , 2020 , 143, 2207-2219	11.2	9
26	Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1524-33	1.2	9
25	P2X7 Receptor Upregulation in Huntington's Disease Brains. <i>Frontiers in Molecular Neuroscience</i> , 2020 , 13, 567430	6.1	8
24	Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3beta. <i>Neuroscience</i> , 2008 , 157, 772-80	3.9	8

23	The neuroprotective transcription factor ATF5 is decreased and sequestered into polyglutamine inclusions in Huntington's disease. <i>Acta Neuropathologica</i> , 2017 , 134, 839-850	14.3	7
22	A mouse model to study tau pathology related with tau phosphorylation and assembly. <i>Journal of the Neurological Sciences</i> , 2007 , 257, 250-4	3.2	7
21	High concordance between hippocampal transcriptome of the mouse intra-amygdala kainic acid model and human temporal lobe epilepsy. <i>Epilepsia</i> , 2020 , 61, 2795-2810	6.4	7
20	Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin. <i>Brain Research Bulletin</i> , 2007 , 72, 121-3	3.9	6
19	The regulation of proteostasis in glial cells by nucleotide receptors is key in acute neuroinflammation. <i>FASEB Journal</i> , 2018 , 32, 3020-3032	0.9	6
18	Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus. <i>Molecular Neurobiology</i> , 2015 , 52, 120-9	6.2	5
17	Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent. <i>PLoS ONE</i> , 2013 , 8, e70952	3.7	5
16	Tau kinase I overexpression induces dentate gyrus degeneration. <i>Neurodegenerative Diseases</i> , 2010 , 7, 13-5	2.3	4
15	Regulation of proteasome activity by P2Y receptor underlies the neuroprotective effects of extracellular nucleotides. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017 , 1863, 43-51	6.9	4
14	Huntington's disease-specific mis-splicing captured by human-mouse intersect-RNA-seq unveils pathogenic effectors and reduced splicing factors		4
13	Huntington's disease-specific mis-splicing unveils key effector genes and altered splicing factors. <i>Brain</i> , 2021 , 144, 2009-2023	11.2	4
12	Prion-Associated Neurodegeneration Causes Both Endoplasmic Reticulum Stress and Proteasome Impairment in a Murine Model of Spontaneous Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
11	Impaired PLP-dependent metabolism in brain samples from Huntington disease patients and transgenic R6/1 mice. <i>Metabolic Brain Disease</i> , 2016 , 31, 579-86	3.9	3
10	Huntingtin-mediated axonal transport requires arginine methylation by PRMT6. <i>Cell Reports</i> , 2021 , 35, 108980	10.6	3
9	A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021 , 142, 159-177	14.3	3
8	Polyadenylation of mRNA as a novel regulatory mechanism of gene expression in temporal lobe epilepsy. <i>Brain</i> , 2020 , 143, 2139-2153	11.2	2
7	Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2018 , 10, 172-183	3.4	2
6	Differential regulation of Kidins220 isoforms in Huntington's disease. <i>Brain Pathology</i> , 2020 , 30, 120-136		1

- 5 CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. *Science Translational Medicine*, **2021**, 13, eabe7104 17.5 ○
- 4 Centro de Biología Molecular "Severo Ochoa": a center for basic research into Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 21, 325-35 4.3
- 3 Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies 203-219
- 2 The Ups in Neurodegenerative Diseases and Aging Huntington's Disease **2006**, 225-235
- 1 Co-expression of FTDP-17 Human Tau and GSK-3 β (or APPSW) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration **2008**, 337-342